Clinical Trials

1,118 enrolled 40 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT06921785 2026-01-09

ARTEMIDE-HCC01

Phase 3 Recruiting

1,220 enrolled

Carcinoma, Hepatocellular

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

114 enrolled

Carcinoma, Hepatocellular

NCT04960709 2025-12-19

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06008093 2025-10-27

TRITON

Phase 3 Recruiting

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

660 enrolled

Carcinoma, Hepatocellular

NCT05557838 2025-02-07

TREMENDOUS

Phase 3 Recruiting

210 enrolled

Carcinoma, Hepatocellular

NCT05301842 2025-01-15

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03509012 2025-01-14

CLOVER

Phase 1/2 Active not recruiting

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

DermatologicGastrointestinalGenitourinary

37 enrolled 13 charts

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02352948 2024-07-26

ARCTIC

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT02616185 2023-11-02

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Phase 1 Terminated

91 enrolled 51 charts

Prostatic Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

72 enrolled 23 charts

Other solid neoplasm

Solid Tumor

NCT03084471 2022-12-22

STRONG

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

26 enrolled

Advanced Malignancy

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02369874 2021-02-10

EAGLE

736 enrolled 26 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

267 enrolled 27 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

39 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

380 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

459 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Other solid neoplasmThoracic

65 enrolled

Part A and B: Advanced Solid Malignancies

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

71 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00257205 2012-07-02

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

655 enrolled

Melanoma

NCT00254579 2012-06-07

Study of CP-675,206 in Refractory Melanoma

251 enrolled

Melanoma

NCT00312975 2012-06-07

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00313794 2012-06-07

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

49 enrolled

Colorectal Neoplasms

NCT00075192 2012-06-06

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Phase 1/2 Completed

8 enrolled

Prostatic Neoplasms

NCT00086489 2012-06-06

CP-675,206 In Patients With Advanced Melanoma

118 enrolled

Melanoma

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

28 enrolled

Carcinoma, Renal Cell

NCT00431275 2012-06-06

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

85 enrolled

Melanoma

NCT00556023 2012-06-06

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

37 enrolled

Pancreatic Neoplasms

NCT00585000 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Phase 1 Terminated

49 enrolled